WO2010062038A3 - Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same - Google Patents
Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same Download PDFInfo
- Publication number
- WO2010062038A3 WO2010062038A3 PCT/KR2009/006050 KR2009006050W WO2010062038A3 WO 2010062038 A3 WO2010062038 A3 WO 2010062038A3 KR 2009006050 W KR2009006050 W KR 2009006050W WO 2010062038 A3 WO2010062038 A3 WO 2010062038A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- isomer
- tyrosine kinase
- pharmaceutical composition
- composition containing
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a compound expressed in the following chemical formula 1, to an isomer thereof, or to a pharmaceutically allowable salt thereof. The compound expressed in chemical formula 1 inhibits the tyrosine kinase activity of Discoidin Domain Receptor 1 (DDR1) and Discoidin Domain Receptor 2 (DDR2), and thus can be valuably used in the prevention or treatment of diseases such as a cancer, hepatocirrhosis, arteriosclerosis, rheumatoid arthritis, osteoarthritis, and the like, which are known to be mainly caused by an excessive activation of Discoidin Domain Receptor 1 or Discoidin Domain Receptor 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2008-0118850 | 2008-11-27 | ||
KR1020080118850A KR101126736B1 (en) | 2008-11-27 | 2008-11-27 | Tyrosine kinase inhibitory compounds, isomers thereof or pharmaceutical acceptable salts thereof, and pharmaceutical composition comprising the same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010062038A2 WO2010062038A2 (en) | 2010-06-03 |
WO2010062038A3 true WO2010062038A3 (en) | 2010-07-22 |
Family
ID=42226201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/006050 WO2010062038A2 (en) | 2008-11-27 | 2009-10-20 | Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101126736B1 (en) |
WO (1) | WO2010062038A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE035589T2 (en) * | 2010-05-26 | 2018-05-28 | Korea Inst Sci & Tech | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same |
US8697708B2 (en) * | 2010-09-15 | 2014-04-15 | F. Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
CN103087077B (en) * | 2011-11-03 | 2016-05-18 | 上海希迈医药科技有限公司 | Thienopyrimidine and furans miazines derivative, its preparation method and in application pharmaceutically |
WO2013068836A1 (en) | 2011-11-07 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis |
CN103360407B (en) * | 2012-04-10 | 2016-06-22 | 上海希迈医药科技有限公司 | A kind of Thienopyrimidine analog derivative, its preparation method and in application pharmaceutically |
CA2927830A1 (en) | 2013-10-23 | 2015-04-30 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinone and isoquinolinone derivative |
KR101540051B1 (en) * | 2013-11-27 | 2015-07-28 | 한국과학기술연구원 | Composition for preventing skin aging or improving skin condition |
TWI676482B (en) | 2017-03-23 | 2019-11-11 | 高雄醫學大學 | Discoidin domain receptor 1 inhibitor and activator and their uses |
CA3178242A1 (en) | 2020-05-25 | 2021-12-02 | Laura Carzaniga | Benzylamine derivatives as ddrs inhibitors |
EP4032896A1 (en) | 2021-01-20 | 2022-07-27 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof |
WO2023210599A1 (en) * | 2022-04-25 | 2023-11-02 | 日本新薬株式会社 | Compound serving as ddr1 kinase inhibitor, and medicine |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040142A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
WO1997013771A1 (en) * | 1995-10-11 | 1997-04-17 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
KR20010031908A (en) * | 1997-11-11 | 2001-04-16 | 실버스타인 아써 에이. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
US20040019065A1 (en) * | 2002-03-01 | 2004-01-29 | Romines William Henry | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use |
-
2008
- 2008-11-27 KR KR1020080118850A patent/KR101126736B1/en active IP Right Grant
-
2009
- 2009-10-20 WO PCT/KR2009/006050 patent/WO2010062038A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040142A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
WO1997013771A1 (en) * | 1995-10-11 | 1997-04-17 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
KR20010031908A (en) * | 1997-11-11 | 2001-04-16 | 실버스타인 아써 에이. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
US20040019065A1 (en) * | 2002-03-01 | 2004-01-29 | Romines William Henry | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use |
Also Published As
Publication number | Publication date |
---|---|
WO2010062038A2 (en) | 2010-06-03 |
KR20100060300A (en) | 2010-06-07 |
KR101126736B1 (en) | 2012-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010062038A3 (en) | Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same | |
WO2006123113A3 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
WO2007095124A3 (en) | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | |
WO2006106326A8 (en) | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors | |
MX2009013077A (en) | 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors. | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
MX2007015863A (en) | Sphingosine kinase inhibitors. | |
UA94622C2 (en) | Kinase innhibitor | |
WO2008022286A3 (en) | Small molecule inhibitors of kynurenine-3-monooxygenase | |
WO2007019251A3 (en) | Sphingosine kinase inhibitors and methods of their use | |
GEP20135785B (en) | Pyrrolopyrimidine compounds as cdk inhibitors | |
WO2005111039A3 (en) | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | |
WO2011052923A3 (en) | Novel 1,6-disubstituted indole compounds as protein kinase inhibitors | |
PL1899329T3 (en) | Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors | |
WO2008118391A3 (en) | Triazinone and diazinone derivatives useful as hsp90 inhibitors | |
WO2008021038A3 (en) | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | |
WO2012028332A8 (en) | Pharmaceutically active compounds as axl inhibitors | |
MX2012013197A (en) | Indazole inhibitors of kinase. | |
NZ623069A (en) | Heat shock protein binding compounds, compositions, and methods for making and using same | |
WO2008011557A3 (en) | Heteroaryl inhibitors of rho kinase | |
HK1154002A1 (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
MY148634A (en) | Pyridazinone derivatives | |
WO2007049041A8 (en) | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer | |
MX2011013325A (en) | 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09829245 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORMS 1205A DATED 03.08.11 AND 02.09.11) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09829245 Country of ref document: EP Kind code of ref document: A2 |